The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
Open accessAbstract
Most cancers are characterized by multiple molecular alterations, but identification of the key proteins involved in these signaling pathways is currently beyond reach. We show that the inhibitor PU-H71 preferentially targets tumor-enriched Hsp90 complexes and affinity captures Hsp90-dependent oncogenic client proteins. We have used PU-H71 affinity capture to design a proteomic approach that, when combined with bioinformatic pathway analysis, identifies dysregulated signaling networks and key oncoproteins in chronic myeloid leukemia. The identified interactome overlaps with the well-characterized altered proteome in this cancer, indicating that this method can provide global insights into the biology of individual tumors, including primary patient specimens. In addition, we show that this approach can be used to identify previously uncharacterized oncoproteins and mechanisms, potentially leading to new targeted therapies. We further show that the abundance of the PU-H71-enriched Hsp90 species, which is not dictated by Hsp90 expression alone, is predictive of the cell’s sensitivity to Hsp90 inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Protein Arginine Methylation in Mammals: Who, What, and Why
Bedford, M. T., & Clarke, S. G. (2009) · Molecular Cell · doi:10.1016/j.molcel.2008.12.013 · Cited by 1,792
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D., Dunford-Shore, B. H., McGrath, S., Hickenbotham, M., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,422
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387
Regulation and Function of IKK and IKK-Related Kinases
Häcker, H., & Karin, M. (2006) · Science's STKE · doi:10.1126/stke.3572006re13 · Cited by 1,274
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
Ren, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1567 · Cited by 878
TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia
Naka, K., Hoshii, T., Muraguchi, T., Tadokoro, Y., Ooshio, T., Kondo, Y., Nakao, S., Motoyama, N., & Hirao, A. (2010) · Nature · doi:10.1038/nature08734 · Cited by 583
Target profiling of small molecules by chemical proteomics
Rix, U., & Superti-Furga, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.216 · Cited by 575
WORKMAN, P., BURROWS, F., NECKERS, L., & ROSEN, N. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.012 · Cited by 521
Self-citationDiverse Cellular Functions of the Hsp90 Molecular Chaperone Uncovered Using Systems Approaches
McClellan, A. J., Xia, Y., Deutschbauer, A. M., Davis, R. W., Gerstein, M., & Frydman, J. (2007) · Cell · doi:10.1016/j.cell.2007.07.036 · Cited by 474
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
Apsel, B., Blair, J. A., Gonzalez, B., Nazif, T. M., Feldman, M. E., Aizenstein, B., Hoffman, R., Williams, R. L., Shokat, K. M., & Knight, Z. A. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.117 · Cited by 440
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Deininger, M. W. N., & Druker, B. J. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.4 · Cited by 365
Structure, function, and regulation of STAT proteins
Lim, C. P., & Cao, X. (2006) · Molecular BioSystems · doi:10.1039/b606246f · Cited by 354
Activity-based protein profiling for biochemical pathway discovery in cancer
Nomura, D. K., Dix, M. M., & Cravatt, B. F. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2901 · Cited by 341
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D., & Rosen, N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609973103 · Cited by 308
Protein tyrosine phosphatases in the JAK/STAT pathway
Xu, D. (2008) · Frontiers in Bioscience · doi:10.2741/3051 · Cited by 307
An, W. G., Schulte, T. W., & Neckers, L. Μ. (2000) · PubMed · Cited by 267
Self-citationHsp90 and co‐chaperones twist the functions of diverse client proteins
Zuehlke, A., & Johnson, J. L. (2010) · Biopolymers · doi:10.1002/bip.21292 · Cited by 251
da Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2632 · Cited by 246
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.27 · Cited by 235
The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells
Klejman, A. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf562 · Cited by 222
Functional proteomics to dissect tyrosine kinase signalling pathways in cancer
Kolch, W., & Pitt, A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2900 · Cited by 200
STAT5 Activation by BCR-Abl Contributes to Transformation of K562 Leukemia Cells
de Groot, R. P., Raaijmakers, J. A. M., Lammers, J.-W. J., Jove, R., & Koenderman, L. (1999) · Blood · doi:10.1182/blood.v94.3.1108.415k07_1108_1112 · Cited by 187
Carayol, N., Vakana, E., Sassano, A., Kaur, S., Goussetis, D. J., Glaser, H., Druker, B. J., Donato, N. J., Altman, J. K., Barr, S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005114107 · Cited by 180
STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5
Paukku, K., & Silvennoinen, O. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.09.001 · Cited by 174
Charting the molecular network of the drug target Bcr-Abl
Brehme, M., Hantschel, O., Colinge, J., Kaupe, I., Planyavsky, M., Köcher, T., Mechtler, K., Bennett, K. L., & Superti-Furga, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900653106 · Cited by 170
The Hsp90 Chaperone Machinery Regulates Signaling by Modulating Ligand Binding Clefts
Pratt, W. B., Morishima, Y., & Osawa, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800023200 · Cited by 162
Salgia, R., Brunkhorst, B. A., Pisick, E. P., Li, J., Lo, S. H., Chen, L. B., & Griffin, J. D. (1995) · PubMed · Cited by 142
Maloney, A., Clarke, P. A., Naaby‐Hansen, S., Stein, R. C., Koopman, J.-O., Akpan, A., Yang, A., Zvelebil, M., Cramer, R., Stimson, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2968 · Cited by 140
The grand challenge to decipher the cancer proteome
Hanash, S., & Taguchi, A. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2918 · Cited by 132
hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling
Nobukuni, T., Kozma, S. C., & Thomas, G. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.019 · Cited by 123
ATPase inhibitors of heat-shock protein 90, second season
Janin, Y. L. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.03.002 · Cited by 95
BCR–ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia
Burke, B. A., & Carroll, M. P. (2010) · Leukemia · doi:10.1038/leu.2010.67 · Cited by 92
Si, J., & Collins, S. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2509 · Cited by 88
Mihailovic, T., Marx, M., Auer, A., Lint, J. V., Schmid, M., Weber, C. K., & Seufferlein, T. T. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0981 · Cited by 87
Purine-Scaffold Hsp90 Inhibitors
Taldone, T., & Chiosis, G. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789895737 · Cited by 74
Self-citationHSP90: The Rosetta stone for cellular protein dynamics?
DeZwaan, D. C., & Freeman, B. C. (2008) · Cell Cycle · doi:10.4161/cc.7.8.5723 · Cited by 73
Transcription Factor STAT5A Is a Substrate of Bruton's Tyrosine Kinase in B Cells
Mahajan, S., Vassilev, A. O., Sun, N., Özer, Z., Mao, C., & Uckun, F. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104874200 · Cited by 65
V600E B‐Rafはその安定性にHsp90シャペロンを要求し,Hsp90阻害剤への応答として分解される
Grbovic, O. M., Basso, A. D., Sawai, A., Ye, Q., Friedlander, P., Solit, D. B., & Rosen, N. X. (2006) · Proceedings of the National Academy of Sciences · Cited by 65
Calpain is a signal transducer and activator of transcription (STAT) 3 and STAT5 protease
Oda, A., Wakao, H., & Fujita, H. (2002) · Blood · doi:10.1182/blood.v99.5.1850 · Cited by 64
Phosphoproteomics and cancer research
Ashman, K., & Villar, E. L. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0369-z · Cited by 56
Katzav, S. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.04.015 · Cited by 52
Novel Hsp90 partners discovered using complementary proteomic approaches
Tsaytler, P. A., Krijgsveld, J., Goerdayal, S. S., Rüdiger, S., & Egmond, M. R. (2009) · Cell Stress and Chaperones · doi:10.1007/s12192-009-0115-z · Cited by 46
Jaganathan, S., Yue, P., & Turkson, J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162669 · Cited by 38
Involvement of SLP-65 and Btk in tumor suppression and malignant transformation of pre-B cells
Hendriks, R. W., & Kersseboom, R. (2005) · Seminars in Immunology · doi:10.1016/j.smim.2005.10.002 · Cited by 23
Cited by
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities
Hu, C., Yang, J., Qi, Z., Wu, H., Wang, B., Zou, F., Mei, H., Liu, J., Wang, W., & Liu, Q. (2022) · MedComm · doi:10.1002/mco2.161 · Cited by 779
Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
Jhaveri, K., Taldone, T., Modi, S., & Chiosis, G. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.10.008 · Cited by 456
Self-citationThe Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
Lackie, R. E., Maciejewski, A., Ostapchenko, V. G., Marques-Lopes, J., Choy, W.-Y., Duennwald, M. L., Prado, V. F., & Prado, M. A. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00254 · Cited by 374
Metadata
- Authors
- Moulick, K., Ahn, J. H., Zong, H., Rodina, A., Cerchietti, L., Gomes DaGama, E. M., Caldas-Lopes, E., Beebe, K., Perna, F., Hatzi, K., Vu, L. P., Zhao, X., Zatorska, D., Taldone, T., Smith-Jones, P., Alpaugh, M., Gross, S. S., Pillarsetty, N., Ku, T., Lewis, J. S., Larson, S. M., Levine, R., Erdjument-Bromage, H., Guzman, M. L., Nimer, S. D., Melnick, A., Neckers, L., & Chiosis, G.
- Venue
- Nature Chemical Biology
- Published
- 2011-09-25
- Volume
- 7
- Issue
- 11
- Pages
- 818-826
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2029431941
- Cited by
- 261
- References
- 45
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.